Physician profile
William Gust Harris
NPI 1922065788
$13,305.03
in general payments reported to CMS, 2019-2025
31 companies · $1,525 in 2025
The $1,525 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,978 · 2020: $1,434 · 2021: $1,636 · 2022: $2,229 · 2023: $2,256 · 2024: $2,247 · 2025: $1,525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,972 · Education: $56.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,972.12 |
| Education | $56.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,687.17 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,339.06 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $1,063.75 | 2020-2025 | Takhzyro, Cuvitru, Hyqvia |
| Genzyme Corporation | $1,017.45 | 2019-2025 | |
| Pfizer INC. | $1,006.41 | 2019-2025 | |
| Leo Pharma INC. | $854.38 | 2022-2025 | Adbry, Anzupgo |
| Csl Behring | $840.85 | 2019-2025 | Hizentra, Haegarda |
| Optinose US, INC. | $725.35 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $680.03 | 2019-2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $657.91 | 2019-2025 | |
| Pharming Healthcare, INC. | $554.59 | 2019-2025 | Ruconest |
| Biocryst US Sales Co., LLC | $547.21 | 2021-2025 | Orladeyo |
| Genentech USA, INC. | $486.68 | 2021-2025 | Xolair |
| Amgen INC. | $447.48 | 2021-2025 | Tezspire |
| Grifols USA, LLC | $341.46 | 2020-2025 | Xembify |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $225.52 | 2019-2020 | |
| Alk-Abello, INC | $126.19 | 2019-2023 | Grastek, Ragwitek, Odactra |
| Shire North American Group INC | $116.27 | 2019 | |
| Incyte Corporation | $103.49 | 2021-2025 | Opzelura |
| Kaleo, INC. | $94.25 | 2019-2024 | Auvi-Q |
| Blueprint Medicines Corporation | $83.45 | 2022-2024 | Ayvakit |
| Octapharma USA, INC. | $66.45 | 2020 | |
| Greer Laboratories, INC. | $62.75 | 2024-2025 | Palforzia, Oralair |
| Cycle Pharmaceuticals INC | $50.71 | 2025 | Sajazir |
| Biocryst Pharmaceuticals, INC. | $29.87 | 2020 | |
| Adma Biomanufacturing LLC | $22.61 | 2021 | |
| Horizon Therapeutics Plc | $17.24 | 2020 | |
| Phadia US INC. | $16.16 | 2021 | |
| Ionis Pharmaceuticals, INC. | $15.18 | 2025 | Dawnzera |
| Sanofi-Aventis U.S. LLC | $14.00 | 2019 | |
| Organon LLC | $11.11 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.